Curasight is built on more than a decade of research in Positron Emissions Tomography (PET) imaging in cancer at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark.

A scientific team led by Professor Andreas Kjaer, developed over the last 8 years the concept of PET imaging of urokinase-type plasminogen activator receptor (uPAR), a known marker of cancer aggressiveness, to be used for improved diagnosis, risk stratification and treatment planning/monitoring in multiple types of cancer.

From a large number of uPAR-PET tracers that were tested by the team in preclinical models, a lead candidate was chosen. In close partnership between Curasight and Rigshospitalet this most promising ligand has been further developed into uTRACEĀ®, the key product of Curasight.